AstraZeneca
Vanderbilt researchers take leadership role in COVID-19 vaccine development
Dec. 18, 2020—Moderna, remdesivir, AstraZeneca. VUMC’s experts have played an integral role in the development of these marquee COVID-19 therapeutics behind the scenes.
COVID-19 long-acting antibodies discovered by Vanderbilt University Medical Center move to phase 3 clinical trials
Oct. 13, 2020—AstraZeneca is advancing into phase 3 clinical trials with an investigational COVID-19 therapy of two long-acting antibodies discovered by Vanderbilt University Medical Center and optimized by AstraZeneca.
Center for Technology Transfer & Commercialization breaks records in rapid facilitation of COVID-19 related agreements
Jul. 9, 2020—To keep pace with Vanderbilt researchers developing COVID-19 solutions, the Center for Technology Transfer & Commercialization has facilitated three license agreements, 11 patent applications and 43 material transfer agreements in record time.
Vanderbilt, AstraZeneca sign new COVID-19 antibody agreement
Jun. 9, 2020—After evaluating the ability of more than 1,500 monoclonal antibodies to bind and neutralize the COVID-19 virus, SARS-CoV-2, in the laboratory, AstraZeneca signed an exclusive license to six candidate antibodies in Vanderbilt’s portfolio.
AstraZeneca, VU collaborate to develop new treatments for major brain disorders
Jan. 14, 2013—AstraZeneca and Vanderbilt University have signed a research collaboration agreement to identify candidate drugs aimed at treating psychosis and other neuropsychiatric symptoms associated with major brain diseases such as Alzheimer’s disease and schizophrenia.